Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,659.00
Bid: 1,939.50
Ask: 1,625.00
Change: 42.50 (2.63%)
Spread: -314.50 (-16.216%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,616.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Covid-19 Hit Sends National Express Lower

Thu, 13th Aug 2020 11:02

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.

----------

FTSE 100 - WINNERS

----------

Just Eat Takeaway, up 2.6%. The online food delivery platform was counting gains after it posted positive interim results on Wednesday. The stock closed up 3.7% on Wednesday.

----------

FTSE 100 - LOSERS

----------

Phoenix Group, down 3.7%, Legal & General, down 1.8%, Aviva, down 2.3%. GlaxoSmithKline, down 2.3%. Royal Dutch Shell A, down 2.2%, Shell B, down 2.1%. The stocks listed in this section all went ex-dividend on Thursday, meaning new buyers no longer qualify for the latest payout.

----------

FTSE 250 - WINNERS

----------

Watches of Switzerland, up 16%. The luxury timepiece retailer said it delivered a strong performance in its maiden year as a public company. For the financial year ended April 26, revenue was up 6% to GBP819.3 million from GBP797.7 million in financial 2019, and adjusted pretax profit was GBP49.4 million, up 86% from GBP26.5 million. For financial 2021, Watches of Switzerland expects revenue in a range between GBP840 million to GBP860 million, on the basis of a continued strong luxury watch market in the UK and US. The company re-opened the majority of its stores during the first quarter, with July registering 7.4% growth in sales versus a year ago, the first full month when the majority of the network was re-opened. June sales were up 0.3%, while May registered a 83% drop.

----------

FTSE 250 - LOSERS

----------

National Express, down 12%. The transport company swung to a bruising loss during a first-half that was focused on limiting the damage from Covid-19, which has battered the public transport sector. The bus, coach and train operator swung to a GBP122.2 million pretax loss in the six months to June 30 from a GBP88.4 million profit a year earlier. Revenue dropped 23% to GBP1.03 billion from GBP1.34 billion. There was no interim dividend, as previously guided, following a 5.16p payout a year ago. There is also no annual profit guidance, due to Covid-19 uncertainty.

----------

Renishaw, down 11%. The British engineering company warned of the continuation of "very challenging" macroeconomic conditions due to the Covid-19 pandemic. For the financial year that ended June 30 pretax profit fell to GBP3.2 million down 97% from GBP109.9 million recorded a year ago. The sharp drop was attributed to restructuring costs, losses in value of financial instruments and financial expenses. Annual revenue fell 11% to GBP510.2 million from GBP574.0 million. Metrology division revenue was lower by 11% at GBP475.2 million, largely as a result of trade tensions between the US and China, weaker demand in the machine tool sector, and the impact of the pandemic. Healthcare revenue decreased by 15% to GBP35.0 million, with Covid-19 causing delays in orders, shipments, installations and postponements of elective surgery. It stated that a final dividend will not be declared in 2020.

----------

TUI, down 4.2%. The Anglo-German holiday firm offered a bleak picture to investors after third-quarter results highlighted how severely hit the travel sector was due to Covid-19 lockdown. Tui reported a pretax loss of EUR1.46 billion for the period ended June 30, swinging from a EUR60 million profit a year before, as revenue plunged 98% to EUR75 million. Third-quarter underlying loss before interest and tax amounted to EUR1.1 billion due to suspension of operations for the majority part of the quarter, resulting in impairment charges and costs arising from ineffective hedging contracts. For the nine months to June-end, the company's revenue fell 41% To EUR6.71 billion, resulting in a sharply widened pretax loss of EUR2.34 billion from a EUR323.3 million loss a year ago. The nine-month underlying Ebit loss amounted to EUR2.0 billion, an increase of EUR1.8 billion versus a year prior, reflected underlying costs of EUR1.3 billion from business suspension since March, impairments triggered totalling EUR410 million, and net costs from ineffective hedges amounting to EUR189 million.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

ASOS, up 3.5%. The online fashion retailer was upgraded to Hold from Sell by Liberum. ASOS on Wednesday said its annual sales and profit are likely to be "significantly ahead of market expectations" as customer returns did not increase as fast as expected.

----------

By Neetika Kurup; neetikakurup@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.